



US009511064B2

(12) **United States Patent**
Pohlmann et al.

(10) **Patent No.:** US 9,511,064 B2
(45) **Date of Patent:** Dec. 6, 2016

(54) **COMBINATION THERAPY FOR THE TREATMENT OF CANCER AND IMMUNOSUPPRESSION**

(71) Applicants: **Basilea Pharmaceutica AG**, Basel (CH); **Universität Basel**, Basel (CH)

(72) Inventors: **Jens Pohlmann**, Basel (CH); **Don Gary Benjamin**, Basel (CH); **Christoph Moroni**, Biel-Benken (CH)

(73) Assignee: **BASILEA PHARMACEUTICA AG**, Bassel (CH)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **14/413,122**

(22) PCT Filed: **Jul. 3, 2013**

(86) PCT No.: **PCT/EP2013/064048**

§ 371 (c)(1),

(2) Date: **Jan. 6, 2015**

(87) PCT Pub. No.: **WO2014/009222**

PCT Pub. Date: **Jan. 16, 2014**

(65) **Prior Publication Data**

US 2015/0157622 A1 Jun. 11, 2015

(30) **Foreign Application Priority Data**

Jul. 10, 2012 (EP) 12175724

(51) **Int. Cl.**

C07D 221/18 (2006.01)

A61K 31/475 (2006.01)

C07D 459/00 (2006.01)

A61K 31/155 (2006.01)

A61K 31/365 (2006.01)

A61K 45/06 (2006.01)

C07D 471/14 (2006.01)

G01N 33/50 (2006.01)

(52) **U.S. Cl.**

CPC **A61K 31/475** (2013.01); **A61K 31/155**

(2013.01); **A61K 31/365** (2013.01); **A61K**

45/06 (2013.01); **C07D 459/00** (2013.01);

C07D 471/14 (2013.01); **G01N 33/5011**

(2013.01); **G01N 2458/00** (2013.01); **G01N**

2500/10 (2013.01)

(58) **Field of Classification Search**

None

See application file for complete search history.

(56)

References Cited

U.S. PATENT DOCUMENTS

2,813,871 A * 11/1957 Lucas C07D 459/00
546/54
8,993,587 B2 * 3/2015 Benjamin A61K 45/06
514/280

2010/0239522 A1 9/2010 Salsbury, Jr. et al.

FOREIGN PATENT DOCUMENTS

WO 2012095379 7/2012
WO 2012095379 A1 * 7/2012

OTHER PUBLICATIONS

Hinke, SA et al., Brit. J. Pharmacol. 2007, vol. 150, pp. 1031-1043.*
Silverman, R. The Organic Chemistry of Drug Design and Drug Action 2004, NY Elsevier, p. 26.*


The International Search Report and Written Opinion, mailed on Aug. 7, 2013, in the related PCT Appl. No. PCT/EP2013/064048.
R. A. Lucas, et al., "Rauwolfsia Alkaloids. XXXI. The Synthesis and Activity of Some Reserpine Analogs," J. Am. Chem. Soc., 1959, 81 (8), pp. 1928-1932.

* cited by examiner

Primary Examiner — Heidi Reese

(57) **ABSTRACT**

The invention relates to novel Rauwolfsia alkaloid derivatives of formula (I) combinations of Rauwolfsia alkaloid derivatives and a mitochondrial inhibitor, e.g. metformin, and the use of Rauwolfsia alkaloid derivatives in combination with mitochondrial inhibitor for the treatment of cancer and for achieving clinical immunosuppression. The invention also relates to a fluorescence-based method for predicting the sensitivity of a cancer cell towards a compound of formula (I).



25 Claims, No Drawings